Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Myositis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    75 result(s) found for: Myositis. Displaying page 3 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2006-005942-35 Sponsor Protocol Number: 1413 Start Date*: 2007-03-14
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Simvastatin therapy in IBM
    Medical condition: inclusion body myositis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028641 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000141-31 Sponsor Protocol Number: ISRCTN30952488 Start Date*: 2016-08-30
    Sponsor Name:London School of Hygiene and Tropical Medicine
    Full Title: A SERIES OF RANDOMISED CONTROLLED N-of 1 TRIALS IN PATIENTS WHO HAVE DISCONTINUED OR WISH TO DISCONTINUE STATIN USE DUE TO MUSCLE-RELATED SYMPTOMS TO ASSESS IF ATORVASTATIN TREATMENT CAUSES MORE MU...
    Medical condition: myalgia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10028411 Myalgia PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002210-23 Sponsor Protocol Number: 1.4botox Start Date*: 2014-10-14
    Sponsor Name:Rigshospitalet
    Full Title: Can local intramuscular botulinum toxin improve dysphagia in patients with myopathic dysphagia and constriction of the cricoid muscle?
    Medical condition: Oculopharyngesl muscle dystrophy, inclusion body myositis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10019897 Hereditary progressive muscular dystrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-000483-25 Sponsor Protocol Number: 01/07 Start Date*: 2007-01-15
    Sponsor Name:OSPEDALE ISRAELITICO DI ROMA
    Full Title: Buprenorfina TDS in old patients with chronic pain not give moderated cancer of intensita serious. Study in open, of Phase IV, not controlled, multicentric, spontaneous
    Medical condition: old patients ultra 65 with chronic pain do not give cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028411 PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002605-22 Sponsor Protocol Number: KZR-616-003 Start Date*: 2020-01-28
    Sponsor Name:Kezar Life Sciences, Inc.
    Full Title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Active Polymyositis or Dermatomy...
    Medical condition: Autoimmune Disorders Polymyositis and Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10003816 Autoimmune disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001597-16 Sponsor Protocol Number: none Start Date*: 2018-07-18
    Sponsor Name:Sitnikova Victoria
    Full Title: Efficacy of botulinum toxin in treating temporomandibular disorders
    Medical condition: Patients are diagnosed TMD (temporomandibular disorder) according to DC/TMD international consortium: myalgia, local myalgia, myofascial pain, myofascial pain with referral.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10028323 Muscle pains HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021430-64 Sponsor Protocol Number: RR10/9389 Start Date*: 2010-12-03
    Sponsor Name:University of Leeds
    Full Title: A randomised double blind placebo controlled clinical trial of anti B-cell therapy in patients with primary Sjögren’s syndrome.
    Medical condition: Primary Sjögren’s syndrome (PSS).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001125-15 Sponsor Protocol Number: ATB-202 Start Date*: 2018-07-16
    Sponsor Name:Atox Bio
    Full Title: Phase III, randomized, double-blind, placebo controlled, parallel-group, study of AB103 as compared to placebo in patients with necrotizing soft tissue infections (NSTI)
    Medical condition: Necrosis of soft tissue infections (NSTI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10065769 Soft tissue necrosis PT
    20.0 10021881 - Infections and infestations 10017068 Fournier's gangrene LLT
    20.1 10021881 - Infections and infestations 10028885 Necrotising fasciitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002301-23 Sponsor Protocol Number: BAP00414 Start Date*: 2005-12-14
    Sponsor Name:Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Full Title: A Phase 3, Randomized, Double-Blind Study Of Ceftobiprole Medocaril Versus Vancomycin With Ceftazidime in The Treatment Of Complicated Skin And Skin Structure Infections
    Medical condition: complicated skin and skin structure infection
    Disease: Version SOC Term Classification Code Term Level
    5.1 10040786 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) LT (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-000305-23 Sponsor Protocol Number: BOS161721-02 Start Date*: 2019-03-20
    Sponsor Name:Boston Pharmaceuticals, Inc.
    Full Title: A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
    Medical condition: Systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-005165-14 Sponsor Protocol Number: TK-254R-0201 Start Date*: 2021-03-25
    Sponsor Name:Teikoku Seiyaku Co Ltd.
    Full Title: Randomized, controlled, double-blind, multi-center trial to evaluate the
    Medical condition: Acute strains, sprains or bruises of the extremities following blunt trauma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10002549 Ankle sprain LLT
    20.0 100000004863 10002550 Ankle sprains and strains LLT
    20.0 100000004863 10028338 Muscle sprains LLT
    20.0 100000004859 10028361 Muscular pain LLT
    21.1 100000004859 10028362 Muscular pains LLT
    20.1 100000004863 10006502 Bruise LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002815-47 Sponsor Protocol Number: ID-064A302 Start Date*: 2023-03-31
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: OPUS-2 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cener...
    Medical condition: Moderate to severe systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002814-17 Sponsor Protocol Number: ID-064A301 Start Date*: 2023-04-04
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe ...
    Medical condition: Moderate to severe systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GR (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002581-35 Sponsor Protocol Number: CL-033-II-02 Start Date*: 2007-09-25
    Sponsor Name:IDEA AG
    Full Title: Multiple dose, double-blind, double-dummy, placebo and active controlled study of pharmacokinetics of Diractin® as well as safety and efficacy for the treatment of muscle soreness from exercise
    Medical condition: The study population is a healthy population who are voluntarily participating in this clinical trial. This study will compare the PK profile after e.c. and oral application of the same dosage of ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028332 Muscle soreness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001514-97 Sponsor Protocol Number: 114541 Start Date*: 2015-05-27
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase 3, observer blind, randomized, non-influenza vaccine comparator-controlled, multi-country and multi-centre study of the efficacy of GSK Biologicals’ quadrivalent, inactivated, split virion,...
    Medical condition: Healthy volunteers (Immunization against influenza in male and female subjects 3 to 8 years of age inclusive)
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004089-13 Sponsor Protocol Number: KLF/K/019811 Start Date*: 2012-05-04
    Sponsor Name:Cassella-med GmbH & Co. KG
    Full Title: Placebo-controlled exploratory pilot study to investigate the effect and onset of action of Traumaplant® for delayed onset muscle soreness.
    Medical condition: delayed onset muscle soreness (DOMS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10028332 Muscle soreness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003613-19 Sponsor Protocol Number: APHP210303 Start Date*: 2021-12-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: AbataCept for the treatment of immune-cHeckpoint inhibitors induced mYocarditiS
    Medical condition: All adult patients with cancer (all cancer types) treated by immune checkpoint inhibitors (anti-PD1, anti-PDL1, anti-CTLA4 monotherapies or combination) and presenting drug-induced myocarditis. The...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004413-13 Sponsor Protocol Number: DIRECT Start Date*: 2021-05-18
    Sponsor Name:Amsterdam UMC, VU University Medical Center
    Full Title: Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early stage NSCLC
    Medical condition: early stage non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001808-11 Sponsor Protocol Number: ID-064A202 Start Date*: 2019-01-14
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe syste...
    Medical condition: Moderate to severe systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) HU (Completed) BG (Completed) PL (Completed) GR (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-003273-10 Sponsor Protocol Number: JBT101-DM-002 Start Date*: 2019-05-21
    Sponsor Name:Corbus Pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
    Medical condition: Dermatomyositis (DM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) CZ (Completed) BG (Completed) SE (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 06:34:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA